Condition
Prostate Cancer Metastatic Castration-Resistant
Total Trials
4
Recruiting
2
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Recruiting2
Active Not Recruiting1
Not Yet Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07354594Phase 2Not Yet RecruitingPrimary
External Beam and Radioligand Radiotherapy for mCRPC
NCT03012321Phase 2Active Not RecruitingPrimary
Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects
NCT07179783Phase 2Recruiting
Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC)
NCT07118436RecruitingPrimary
Liquid Biopsy Under PSMA Radioligand Therapy
Showing all 4 trials